Revolution Medicines, Inc. (RVMD) SEC Filings, Jun-Aug 2026

Revolution Medicines, Inc. (RVMD) received a notice under Rule 144 that Jeffrey Todd Cislini plans to sell restricted common stock through Morgan Stanley Smith Barney LLC. The notice covers up to 75,894 shares of common stock, with an aggregate market value of $16,069,416.09, on or after August 21, 2026 on the NASDAQ.

The securities to be sold include shares underlying restricted stock units and shares issuable upon the exercise of stock options from the issuer. RVMD had 214,336,418 shares outstanding at the time referenced. Cislini also reports having sold 2,157 shares for $336,748.90 during the prior three months.

Baker Bros. Advisors LP and related parties report passive ownership in Revolution Medicines, Inc. The reporting group, including Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, and managing members Julian C. Baker and Felix J. Baker, reports beneficial ownership of 11,443,357 shares of Revolution Medicines common stock. This represents 5.3% of the company’s common stock, based on 214,242,688 shares outstanding as of June 30, 2026, as referenced from the issuer’s Form 10-Q. The shares are held by investment funds Baker Brothers Life Sciences, L.P. and 667, L.P., over which the Adviser has complete discretion. The reporting persons state they have sole voting and dispositive power over these shares and no shared voting or dispositive power.

Farallon Capital Management, L.L.C. and affiliated investment funds report beneficial ownership in Revolution Medicines, Inc. common stock. The Farallon Funds hold 13,550,796 Shares and 120,085 Common Stock Purchase Warrants, which are treated as exercisable within 60 days, resulting in beneficial ownership of 13,564,149 Shares, or 6.4% of the outstanding common stock. The Warrants are subject to a 9.99% Beneficial Ownership Limitation, which currently does not restrict exercise. Dividends and sale proceeds are payable to the Farallon Funds, while Farallon Capital Management and certain managing members share voting and dispositive power over the reported securities.

Janus Henderson Group Ltd., through its asset management subsidiaries, reports beneficial ownership of 10,736,145 shares of Revolution Medicines, Inc. common stock, representing 5.1% of the class. These shares are held across multiple managed portfolios for clients of various Janus Henderson asset managers.

The group has shared voting power and shared dispositive power over all 10,736,145 shares, with no sole voting or dispositive power. The managed portfolios, not Janus Henderson itself, have the right to receive all dividends and sale proceeds, and no individual managed portfolio holds more than five percent of Revolution Medicines’ common stock.

Revolution Medicines, a late-stage oncology company focused on RAS-addicted cancers, reported sharply higher spending and losses for the quarter and six months ended June 30, 2026. Research and development expense was $394,919 (in thousands) for the quarter versus $224,134 (in thousands) a year earlier, while general and administrative expense rose to $110,213 (in thousands) from $40,580 (in thousands). Quarterly net loss widened to $644,371 (in thousands), including a $151,031 (in thousands) non-cash loss from the change in fair value of warrant liabilities.

For the first half of 2026, net loss reached $1,098,187 (in thousands). To fund its expanding clinical pipeline, the company raised substantial capital, including a follow-on equity offering of 12,147,887 shares at $142.00 per share for net proceeds of approximately $1,651,354 (in thousands), at-the-market sales, $500,000 (in thousands) from two tranches of a Royalty Purchase Agreement, and $500,000 (in thousands) of 0.50% convertible senior notes due 2033. At June 30, 2026, cash and cash equivalents were $815,435 (in thousands) and marketable securities were $3,122,534 (in thousands), with total assets of $4,323,270 (in thousands). Management states that this cash, cash equivalents and marketable securities will fund planned operations for at least 12 months.

Revolution Medicines reported a second-quarter 2026 net loss of $644.4 million, compared with $247.8 million a year earlier, driven by R&D expenses of $394.9 million and G&A of $110.2 million as late-stage development and commercialization activities expanded. Cash, cash equivalents and marketable securities were $3.9 billion as of June 30, 2026, supported by $2,225.0 million in April equity and convertible offerings and a $250.0 million Royalty Pharma payment, with up to $1.5 billion of additional committed capital remaining. Full-year 2026 GAAP operating expenses are guided to $2.1–$2.2 billion, including $270–$290 million of stock-based compensation.

Regulatory and clinical progress was substantial. FDA accepted the daraxonrasib NDA in previously treated metastatic pancreatic cancer, EMA began a phased review, and more than 2,000 patients have received daraxonrasib via a U.S. Expanded Access Program; daraxonrasib also received FDA Breakthrough Therapy Designation in certain previously treated metastatic RAS mutant NSCLC. Combination data in first-line NSCLC showed high response rates for zoldonrasib and elironrasib, supporting multiple ongoing or planned global Phase 3 RASolute and RASolve trials alongside earlier-stage RAS(ON) programs and industry collaborations.

BlackRock, Inc. reports beneficial ownership of 12,201,395 shares of REVOLUTION MEDICINES INC common stock, representing 5.7% of the class. BlackRock has sole voting power over 11,508,777 shares and sole dispositive power over 12,201,395 shares, with no shared voting or dispositive power reported.

The holdings are attributed to certain BlackRock business units, and the economic benefits from these shares are held by various underlying clients. Other persons may receive dividends or sale proceeds, but no single such person is reported to have more than five percent of the company’s outstanding common shares.

Revolution Medicines director Sushil Patel reported option exercises and share sales in RVMD stock. On June 29, 2026, he exercised stock options to acquire 2,955 shares of common stock at an exercise price of $37.54 per share and sold 5,580 shares in a series of open-market transactions.

The sales were executed at weighted-average prices within ranges from $182.93 to $192.64 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on March 30, 2026. After these transactions, Patel directly held 21,656 common shares, including 1,191 restricted stock units.

RVMD reported a Form 144 notice listing proposed sales of Common Stock through Morgan Stanley Smith Barney LLC. The filing lists an exercise of stock options covering 2,955 shares with a sale date of 06/29/2026 and 2,625 Restricted Stock Units with an original date of 06/15/2024.